Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Celldex Therapeutics, Inc. Surged on Thursday

By Cory Renauer – Nov 8, 2018 at 5:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's third-quarter earnings report gave investors lots to look forward to.

What happened

Shares of Celldex Therapeutics, Inc. (CLDX -0.85%), a clinical-stage biotech developing novel new cancer therapies, rose 11.8% following the company's third-quarter earnings report on Thursday. Progress with several clinical-stage candidates during the three months ended Sept. 30 sets the company up for potential catalysts in the quarters ahead.

So what 

Celldex shares have been hammered mercilessly since its lead candidate failed a pivotal study earlier this year. Today, Celldex provided progress updates for a handful of new drug candidates in clinical-stage development, which gives the company at least a few chances to mount a comeback.

Person drawing an upward sloping chart.

Image source: Getty Images.

A phase 1 study testing the company's CD40 targeted antibody, CDX-1140, in a variety of solid tumors has completed dosing the first four cohorts and continues to exhibit a desirable safety profile. A phase 2 combination study of CDX-3379 and Erbitux in advanced head and neck cancer has nearly finished enrolling patients, so we should find out if this program has legs before much longer.

Now what

Celldex finished September with $105.6 million in cash and marketable securities after operations lost $7.7 million during the third quarter. At this rate, it's going to be a while before Celldex needs to visit the equity tap again. That said, investors were also pleased to hear that Celldex shares will most likely stay on the Nasdaq exchange despite not meeting the $1.00 minimum.

The company plans to transfer to the Nasdaq Capital Market exchange for 180 days beginning later this month. If results from ongoing programs don't lift the stock past the minimum bid threshold by then, Celldex intends to implement a reverse stock split to maintain its listing.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics and Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
$28.11 (-0.85%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.